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Abstract: BACKGROUND Many testicular germ cell cancers are curable despite metastatic disease, but
about 10-15% of patients fail cisplatin-based first-line treatment. Immunotherapy is considered as addi-
tional treatment approach for these patients. Inhibition of the interaction between Programmed Death
Receptor 1 (PD-1) and Programmed Death Receptor Ligand 1 (PD-L1) enhances T-cell responses in vitro
and mediates clinical antitumour activity. We analysed the expression of PD-L1 in testicular germ cell
tumours to evaluate its potential as target for immunotherapeutic strategies. METHODS Immunohisto-
chemistry was performed in 479 formalin-fixed paraffin-embedded specimens using a rabbit monoclonal
antibody (E1L3N). The tissue microarray consisted of 208 pure seminomas, 121 non-seminomas, 20 in-
tratubular germ cell neoplasia unclassified (IGCNU) and 20 specimens of non-neoplastic testicular tissue.
RESULTS Programmed Death Receptor Ligand-1 expression was found in 73% of all seminomas and in
64% of all non-seminomas. None of 20 IGCNU and none of 20 normal tissue specimens exhibited PD-L1
expression. PD-L1 positive stromal cells were only detected in seminomas, but not in non-seminomas.
The anti PD-L1 antibody showed a pre-dominantly membranous staining pattern in testicular tumour
cells, as well as expression in stromal cells. CONCLUSIONS This frequent expression of PD-L1 in human
testicular germ cell tumours suggests that patients with testicular germ cell tumours could profit from
immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies.
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Background:Many testicular germ cell cancers are curable despite metastatic disease, but about 10–15% of patients fail cisplatin-
based first-line treatment. Immunotherapy is considered as additional treatment approach for these patients. Inhibition of the
interaction between Programmed Death Receptor 1 (PD-1) and Programmed Death Receptor Ligand 1 (PD-L1) enhances T-cell
responses in vitro and mediates clinical antitumour activity. We analysed the expression of PD-L1 in testicular germ cell tumours to
evaluate its potential as target for immunotherapeutic strategies.
Methods: Immunohistochemistry was performed in 479 formalin-fixed paraffin-embedded specimens using a rabbit monoclonal
antibody (E1L3N). The tissue microarray consisted of 208 pure seminomas, 121 non-seminomas, 20 intratubular germ cell
neoplasia unclassified (IGCNU) and 20 specimens of non-neoplastic testicular tissue.
Results: Programmed Death Receptor Ligand-1 expression was found in 73% of all seminomas and in 64% of all non-seminomas.
None of 20 IGCNU and none of 20 normal tissue specimens exhibited PD-L1 expression. PD-L1 positive stromal cells were only
detected in seminomas, but not in non-seminomas. The anti PD-L1 antibody showed a pre-dominantly membranous staining
pattern in testicular tumour cells, as well as expression in stromal cells.
Conclusions: This frequent expression of PD-L1 in human testicular germ cell tumours suggests that patients with testicular germ
cell tumours could profit from immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies.
Testicular germ cell tumours are curable despite the presence of
metastatic disease. Nevertheless, about 10–15% of patients fail
cisplatin-based first-line chemotherapy and about 3–5% of all
patients with testicular germ cell tumours will eventually die of
their disease. Moreover, short- and long-term side effects of
cisplatin-based chemotherapy make the search for new and less
toxic treatment strategies worthwhile.
Programmed Death Receptor 1 (PD-1, CD279) is one of the
members of the extended family of T-cell regulators expressed
on the surface of activated T cells, B cells and macrophages
(Keir et al, 2008). Its ligand, Programmed Death Receptor
Ligand 1 (PD-L1) (B7-H1, CD274), is expressed on tumour cells,
macrophages, T cells and certain other tissue types (Keir et al,
2008). The interaction of these two molecules negatively regulates
immune responses. Of major interest is that inhibition of the
interaction between PD1 and PD-L1 can enhance T-cell
responses in vitro and mediates clinical antitumour activity
(Berger et al, 2008). PD-L1 expression in tumour specimens has
been described as a predictive marker for tumour response to
anti-PD1 or -PD-L1 immunotherapy in various advanced
tumours, including melanoma, non-small cell lung cancer, kidney
cancer, colorectal cancer, castration-resistant prostate cancer and
bladder cancer (Berger et al, 2008). For example, in bladder
cancer, a disease that has not seen therapeutic advances for
several decades, the anti-PD-L1 antibody MPDL3280A demon-
strate antitumour responses with objective response rates up to
53% in patients with PD-L1-positive tumours and 13% in PD-L1-
negative tumours (Powles et al, 2014). In metastatic melanoma
one-third showed objective tumour regressions to the anti PD-1
agent Nivolumab with a median response duration of 2 years
(Topalian et al, 2014). The aim of this study was to investigate the
expression of PD-L1 in testicular germ cell tumours.
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MATERIALS AND METHODS
Formalin-fixed paraffin-embedded tumour specimens from 329
patients diagnosed with primary testicular germ cell tumours were
retrieved from the Institute of Surgical Pathology of the University
Hospital Zurich, Switzerland from 1990 to 2003. The patient age
ranged from 18 to 90 with a median of 33.5 years. Tumours were
classified according to the 2004 WHO Classification. A tissue
microarray was constructed and included a total of 208 pure
seminomas and 121 non-seminomas or mixed tumours as
described previously (Bode et al, 2011). In mixed germ cell
tumours, each tumour component (seminomatous, embryonal
carcinoma, yolk sac tumour, choriocarcinoma, teratoma) was
separately punched. Briefly, the tissue microarray consisted of the
following tumour components: 248 seminomas, 87 embryonal
carcinomas, 48 yolk sac tumours, 46 teratomas and 10 chor-
iocarcinomas. Furthermore, 20 samples of normal testicular tissue
as well as 20 samples of intratubular germ cell neoplasia
unclassified were included.
To detect the PD-L1 protein, we used the monoclonal rabbit
antibody (E1L3N, Cell Signaling Technology, Inc. (CST), Danvers,
MA, USA). A multi-tumour tissue microarray was used to establish
a staining protocol for the PD-L1 antibody. A dilution of 1:1000
resulted in a strong and distinct membranous signal without
unspecific background staining in positive controls (PD-L1-
positive lung cancer cases). Programmed Death Receptor Ligand-
1-negative lung cancer cases were used as negative controls.
An experienced uropathologist (PKB) evaluated all tissue micro-
array spots. All results were re-evaluated by a second observer
(CDF). In discrepant cases, consensus was achieved between the
two observers after individual case discussion. Percentages of
PD-L1-positive tumour cells and staining pattern were evaluated
for each punch. Programmed Death Receptor Ligand-1 expression
was recorded if a distinct membranous staining signal on the tumour
cell surface or strong cytoplasmic staining within the tumour or
stromal cells was observed. A 5% cut-off value was applied for
PD-L1 positivity as it has been proposed in non-small cell lung
cancer (Zhang et al, 2015). To evaluate the overall tumour expression
of non-seminomas, tumours with multiple components were
considered PD-L1-positive if any component met these criteria.
RESULTS
Programmed Death Receptor Ligand-1 expression was found in
73% of seminomas and 64% of non-seminomas. The expression in
the individual tumour components is shown in Figure 1 and
summarised in Table 1. None of the 20 precursor lesions and none
of the 20 normal testicular specimens exhibited PD-L1 expression.
Correlation with tumour stage showed PD-L1 expression in 53%
(pT1), 66% (pT2) and 70% (pT3).
In general, PD-L1 expression was found to be heterogeneous in
the tumour tissue showing dispersed positive foci. Furthermore,
differences between seminoma and non-seminoma were noted.
The seminoma components showed a positive staining predomi-
nantly in the interface region between tumour and fibrovascular
stromal septae. Frequently, some seminoma cells showed a distinct
membranous staining. In the stromal septae, it was difficult to
evaluate which exact cells (lymphocytes, stromal cells, endothelial
cells) were positive because of the marked density of the cellular
infiltrate in the stroma, but it seemed that it was mainly restricted
to the lymphocytes. Most cases of non-seminoma components
showed a distinct strong membranous staining of the tumour cells
and only rarely expression in the tumour stroma was noted.
DISCUSSION
In this study, we observed frequent PD-L1 expression in testicular
germ cell tumours, but not in their precursor lesion (intratubular
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Figure 1. Programmed cell death ligand 1 (PD-L1) staining in several tumour components: Classic seminoma with distinct membrane staining in
a small focus (A); Classic seminoma with typical stromal staining pattern (B); Embryonal carcinoma with typical membranous staining pattern (C);
Yolk sac tumour with distinct membrane staining in a small focus (D); choriocarcinoma with strong membrane staining in dispersed tumour
cells, predominantly multinucleated giant cells (E); Embryonal carcinoma with a small focus demonstrating the marked heterogeneity of PD-L1
expression (F).
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germ cell neoplasia unclassified). Importantly, normal testis was
PD-L1 negative, too. The frequent expression of PD-L1 in this
cohort is comparable with other genitourinary cancer like renal cell
carcinoma (66%) (Thompson et al, 2005) and bladder cancer
(20%) (Faraj et al, 2015) or non-genitourinary cancers like breast
cancer (23.4%) (Muenst et al, 2014) or colorectal cancer (36%)
(Droeser et al, 2013). In these tumours, the positive expression of
PD-L1 has been described to be associated with shorter overall
survival (Zhang et al, 2015). Furthermore, clinical trials suggested
that the tissue expression status of PD-L1 is the most important
marker to predict therapy response to PD-1 and PD-L1
immunotherapy (Berger et al, 2008). A major limitation of our
study might be the lack of clinical follow-up data. Nevertheless, our
accurate description of PD-L1 expression in testicular germ cell
tumours forms the basis for a potential use of PD-L1 as predictive
marker in future PD-L1 immunotherapies.
We conclude that the frequent expression of PD-L1 in testicular
seminomas and non-seminomas indicates that immune checkpoint
blockade could be a promising new treatment approach also in
testicular cancer that warrants further investigation in clinical
trials.
Take home message. Frequent PD-L1 expression in testicular
germ cell tumours indicates that PD-L1 immunotherapy might be
a novel option in the treatment of testicular cancer.
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Table 1. Summary of PD-L1 expression for individual tissue
types, tumour components and tumour stage
Tissue types Negative Weak Strong
Positive
cases
(%)
Seminoma (n¼ 208) 57 67 84 73%
Non-seminoma (n¼ 121) 43 35 43 64%
Intratubular germ cell neoplasia 20 0 0 0%
Normal testis 20 0 0 0%
Individual tumour components
Seminomatous (n¼ 248) 77 77 94 69%
Choriocarcinoma (n¼ 10) 2 2 6 80%
Yolk sac tumour (n¼48) 29 12 7 40%
Embryonal carcinoma (n¼87) 34 29 24 61%
Teratoma (n¼46) 39 5 2 13%
Tumour stage
pT1 (n¼ 352) 164 83 105 53%
pT2 (n¼ 94) 32 38 24 66%
pT3 (n¼ 10) 3 3 4 70%
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